← Leaderboards
Tal Danino
Columbia Univ New York Morningside
$10,808,082
Attributed
$16,958,204
Total exposure
12
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2013–25$5M$3.8M$2.5M$1.3M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,958,204 · 12
By mechanism
R01$11,953,013 · 6
U01$2,937,508 · 1
UG3$727,904 · 1
R00$651,369 · 1
R21$523,549 · 1
K99$84,741 · 1
Top collaborators
- Nicholas Arpaia16 shared
- Jeff M Hasty4 shared
- Lev S Tsimring4 shared
- Kam W Leong3 shared
Most similar at Columbia Univ New York Morningside
Same institution · by research overlap
- Nicholas Arpaia$10,668,029
- Amer Aziz Beg$7,960,036
Others in their field
Top investigators on “Engineering”
- David Heimbrook · Leidos Biomedical Research, Inc.$265,348,415
- Francis L Halzen · University Of Wisconsin-Madison$239,306,664
- Lisa Garcia Bedolla · University Of California-Berkeley$175,927,128
- Daniel Stanzione · Arizona State University$173,674,275
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$173,157,760
- Kiyoshi Suyehiro · Iodp Management International, Inc$166,539,344
Research focus
EngineeringTumorBacteriaMouse ModelSynthetic BiologyCytolysisSpecificityMalignant NeoplasmsGrowthProductionCellsEnvironmentGeneticSolid NeoplasmToxic EffectSafetyProbioticsIn Vivo Imaging SystemCancer TherapyClinical TrialsOralNeoplasm MetastasisEscherichia ColiTumor Microenvironment
Grant awards (38)
Engineered probiotic bacteria for colorectal cancer immunoprevention and interception$727,904
UG3 · FY2025 · CA
Modulating the localization and persistence of microbial neoantigen vaccine vectors to enhance therapeutic efficacy$638,120
R01 · FY2025 · CA
Programmable encapsulation systems to improve delivery of therapeutic bacteria$619,930
R01 · FY2025 · EB · contact PI
Programmable encapsulation systems to improve delivery of therapeutic bacteria$617,386
R01 · FY2024 · EB · contact PI
Engineering immunotherapeutic probiotics to mitigate irAE$571,668
U01 · FY2024 · CA · contact PI
Modulation of the tumor microenvironment with probiotic therapies$525,502
R01 · FY2024 · CA · contact PI
Engineering S. typhimurium for metastatic colorectal cancer$352,142
R01 · FY2024 · EB · contact PI
Probiotic guided CAR-T therapy (ProCARs) for breast cancer$664,480
R01 · FY2023 · EB · contact PI
Programmable encapsulation systems to improve delivery of therapeutic bacteria$613,945
R01 · FY2023 · EB · contact PI
Engineering immunotherapeutic probiotics to mitigate irAE$599,683
U01 · FY2023 · CA · contact PI
Modulation of the tumor microenvironment with probiotic therapies$551,862
R01 · FY2023 · CA · contact PI
Engineering S. typhimurium for metastatic colorectal cancer$357,852
R01 · FY2023 · EB · contact PI
Engineering probiotics for tuberculosis therapy$233,850
R21 · FY2023 · AI · contact PI
Modulation of the tumor microenvironment with probiotic therapies$86,602
R01 · FY2023 · CA · contact PI
Probiotic guided CAR-T therapy (ProCARs) for breast cancer$676,866
R01 · FY2022 · EB · contact PI
Engineering immunotherapeutic probiotics to mitigate irAE$584,146
U01 · FY2022 · CA · contact PI
Modulation of the tumor microenvironment with probiotic therapies$561,341
R01 · FY2022 · CA · contact PI
Engineering S. typhimurium for metastatic colorectal cancer$350,841
R01 · FY2022 · EB · contact PI
Engineering probiotics for tuberculosis therapy$289,699
R21 · FY2022 · AI · contact PI
Modulation of the tumor microenvironment with probiotic therapies$85,800
R01 · FY2022 · CA · contact PI
Probiotic guided CAR-T therapy (ProCARs) for breast cancer$675,112
R01 · FY2021 · EB · contact PI
Engineering immunotherapeutic probiotics to mitigate irAE$595,682
U01 · FY2021 · CA · contact PI
Modulation of the tumor microenvironment with probiotic therapies$582,197
R01 · FY2021 · CA · contact PI
Engineering immunotherapeutic probiotics to mitigate irAE$43,377
R01 · FY2021 · CA · contact PI
Probiotic guided CAR-T therapy (ProCARs) for breast cancer$660,386
R01 · FY2020 · EB · contact PI
Modulation of the tumor microenvironment with probiotic therapies$591,316
R01 · FY2020 · CA · contact PI
Engineering immunotherapeutic probiotics to mitigate irAE$586,329
U01 · FY2020 · CA · contact PI
Engineering S. typhimurium for metastatic colorectal cancer$346,661
R01 · FY2020 · EB · contact PI
Engineered gene circuits for basic science and biotechnology$578,402
R01 · FY2019 · GM
Engineered gene circuits for basic science and biotechnology$582,194
R01 · FY2018 · GM
Programmable Probiotics for Cancer$181,689
R00 · FY2018 · CA · contact PI
Engineered gene circuits for basic science and biotechnology$586,223
R01 · FY2017 · GM
Programmable Probiotics for Cancer$220,680
R00 · FY2017 · CA · contact PI
Engineered gene circuits for basic science and biotechnology$604,476
R01 · FY2016 · GM
Programmable Probiotics for Cancer$249,000
R00 · FY2016 · CA · contact PI
Programmable Probiotics for Cancer$84,741
K99 · FY2015 · CA · contact PI
Bacterial Minicells for Cancer Therapeutics$27,930
F32 · FY2015 · CA · contact PI
Bacterial Minicells for Cancer Therapeutics$52,190
F32 · FY2013 · CA · contact PI